Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
Burris, Howard A × Lebrun, Fabienne Rugo, Hope S Beck, J Thaddeus Piccart, Martine Neven, Patrick Baselga, Jose Petrakova, Katarina Hortobagyi, Gabriel N Komorowski, Anna Chouinard, Edmond Young, Robyn Gnant, Michael Pritchard, Kathleen I Bennett, Lee Ricci, Jean-Francois Bauly, Hounayda Taran, Tetiana Sahmoud, Tarek Noguchi, Shinzaburo #
John Wiley & Sons
Cancer vol:119 issue:10 pages:1908-15
The randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression-free survival with the use of everolimus plus exemestane (EVE + EXE) versus placebo plus exemestane (PBO + EXE) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors. This analysis investigated the treatment effects on health-related quality of life (HRQOL).